Amrutha Siri, a 27-year-old woman, arrived at SLNS Hospital seeking relief from a challenging set of health issues. For five years, she had been grappling with Polycystic Ovary Syndrome, which significantly disrupted her life. Her menstrual cycles were irregular, lasting between 36 to 40 days, with a flow duration of 4 to 6 days.
Three years ago, Amrutha experienced a remarkable reversal of her PCOD symptoms, bringing her much-needed respite. However, her symptoms returned, causing her significant distress. Adding to her challenges, Amrutha developed knee pain and irritable bowel syndrome two years ago associated with acidity, indigestion and bloating further complicating her daily life and making it difficult for her to maintain her usual active lifestyle. Desperate for a solution, she turned to SLNS Hospital, hoping for a comprehensive treatment plan to restore her health and bring her life back on track.
| S.NO | BIOMARKER | DAY 1 | DAY 20 |
| 1 | LH | 7.9 | 9.01 |
| 2 | PROLACTIN | 52.9 | 18.7 |
| 3 | FREE ANDROGEN INDEX | 9.7 | 4.29 |
| 4 | FREE TESTOSTERONE | 2.23 | 1.73 |
| 5 | TESTOSTERONE | 59.6 | 56.2 |
| 6 | AMH (ANTI MULLERIAN HORMONE) | 6.37 | 11.87 |
| 7 | DHEA-S | 161 | 170.8 |
| 8 | FSH | 3.37 | 2.94 |
| 9 | E2 (ESTRADIOL) | 79 | 204 |
| 10 | SHBG (SEX HORMONE BINDING GLOBULIN) | 21.3 | 45.4 |
| 11 | FASTING INSULIN | 20.68 | 5.19 |
| 12 | HOMA IR | 4.81 | 1.05 |
TREATMENT FORECAST
The analysis of hormonal parameters before and after treatment reveals significant progress in managing the patient’s health issues. Initially, on June 1, 2024, during the ovulation phase, the patient’s LH was 7.9, below the normal range of 8.7-76.3. By July 5, 2024, in the luteal phase, LH had increased to 9.01, which, while still within the normal range of 0.5-16.9, indicates a positive progression. LH is crucial for triggering ovulation, and this increase reflects an improvement in ovulatory function.
Prolactin levels were significantly high before treatment at 52.9, which can adversely affect ovarian follicles. Post-treatment, prolactin dropped to 18.7, marking a substantial improvement and indicating enhanced ovarian and pituitary function.
The Free Androgen Index decreased from 9.7 to 4.29, showcasing a great reduction in androgens. Lower androgen levels help mitigate symptoms like hirsutism and ovarian cysts. Similarly, free testosterone levels fell from 2.23 to 1.73, which further supports the reduction of hirsutism and cyst formation.
Anti-Müllerian Hormone levels raise from 6.37 to 11.87, an extraordinary improvement that suggests an increase in the number of available eggs, thus benefiting fertility in PCOS.
DHEA-S increased slightly from 161 to 170.8, which may support hormonal balance and ovulation. Follicle-Stimulating Hormone (FSH) decreased from 3.37 to 2.94, reflecting the normal shift from follicle development to corpus luteum function post-ovulation.
Estradiol (E2) levels surged from 79 to 204, an extraordinary extent indicating improved menstruation and fertility. SHBG also increased from 21.3 to 45.4, signaling enhanced hormonal balance and metabolic health.
Lastly, fasting insulin levels dropped from 20.68 to 5.19, showcasing great progress in reducing insulin resistance, a common issue in PCOS. Overall, these changes represent significant advancements in managing the patient’s hormonal health and PCOS symptoms.
Restored her digestive health, addressing issues such as bloating, acidity, and indigestion through naturopathic modalities.